AU Patent

AU2024269205A1 — Dsrna molecules for regulating masp2 gene activity

Assigned to Rona Bioscience Ltd · Expires 2025-12-11 · 0y expired

What this patent protects

Provided are a double-stranded RNA used to inhibit the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in cells, cells containing nucleotides encoding the same, and a method of using the dsRNA or cells to treat diseases or symptoms mediated or associated …

USPTO Abstract

Provided are a double-stranded RNA used to inhibit the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in cells, cells containing nucleotides encoding the same, and a method of using the dsRNA or cells to treat diseases or symptoms mediated or associated with MASP2 expression in subjects.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024269205A1
Jurisdiction
AU
Classification
—
Expires
2025-12-11
Drug substance claim
No
Drug product claim
No
Assignee
Rona Bioscience Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.